

Effector Cell Institute, Inc  
(Nagoya Stock Market, Centrex:4567)  
4-7-7 Aobadai Meguro-Ku,  
Tokyo 153-0042  
Japan

June 6, 2008

## **ECI Enters into Partnership with Fujinon Corporation**

Effector Cell Institute, Inc (ECI) is pleased to announce that it has come to agreement on partnership with Fujinon Corporation<sup>1)</sup>, one of the FUJIFILM Corporation Group companies specializing in optical devices, with respect to manufacture by commissioning of ECI's new products described below (original equipment manufacture -OEM-). This agreement is based on the resolution adopted by the company's board of directors at its meeting held today.

Our cell function analysis systems developed by applying TAXIScan™ technology<sup>2)</sup>, which is our proprietary cell-based assay technology, are highly acclaimed by laboratories and medical institutions throughout the world.

Fujinon Corporation is internationally recognized for its optical device manufacturing technology. The general business tie-up agreement to be concluded this time focuses on the manufacture by commissioning of our new products (original equipment manufacture -OEM-) by Fujinon Corporation, with the perspective of strengthening our marketing and sales area for TAXIScan™ cell-based assay devices so as to achieve further expansion of our business.

### Expected Effects

Effects of this agreement upon the company's business performance will be announced as soon as they become evident.

### Glossary

#### 1) Fujinon Corporation

Being a FUJIFILM Corporation Group company specializing in optical devices, the company is a topline manufacturer in the fields of medical endoscopes (nasal) and industrial lenses.

Paid-in capital: 500 million yen (as of end of May 2008)

Employees: 1,330 (as of end of May 2008)

#### 2) TAXIScan™ technology

TAXIScan™ technology is ECI's unique, core technology for cell function analysis that supports the company's cell-based drug discovery (CDD) activities. Using this proprietary technology, ECI is doing much for the progress of personalized medicine, including the discovery of new biomarkers useful for new drug development through the collaboration agreement concluded with AstraZeneca Plc., UK, one of the global leading pharmaceutical companies.

(Contacts for inquiries or additional information)

Effector Cell Institute, Inc Administrative Department Tel: +81-3-5452-0662(DID) Fax: +81-3-5452-0663 <a href="http://www.effectorcell.co.jp">http://www.effectorcell.co.jp</a>
--